At IMD-Pharma, we’re developing a new class of drug to treat Chronic Inflammatory Diseases (CIDs) like Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis by re-balancing the dysregulated immune system, as oppose to using broad immunosuppression. The molecular platforms we design and conceive show unprecedented control of inflammation and neuro-inflammation by promoting a pro-resolutive immune response whilst controlling the pro-inflammatory response.
The company was founded in 2016 by Rémy Poupot, Cédric-Olivier Turrin and Serge Calet.
First discovered in INSERM and CNRS laboratories by Cédric-Olivier TURRIN and Rémy POUPOT, IMD-Pharma’s technology is the subject of 4 patents for which IMD-Pharma holds exclusive worldwide licenses in human and animal health.
CEO & cofounder
Cédric-Olivier Turrin (Ph.D.)
Cédric-Olivier has over 25 years of experience on the study and development of multivalent macromolecules and molecular trees (dendrimers) for biomedical applications. Macromolecular chemist by training, Cédric-Olivier has co-edited two books, co-authored 100 peer-reviewed articles and 7 patents in the dendrimer field. Cédric-Olivier has recently stepped out of academic research and he is CEO of IMD-Pharma since october 2021.
Cofounder and advisor
Rémy Poupot (Ph.D.)
Rémy has over 25 years of experience at the frontier between immunology and biochemistry. He has a strong expertise in the development of new therapies for the treatment of chronic inflammatory diseases. Full-professor at the University Paul Sabatier of Toulouse (Fr) and head of a research group at Infinity, Rémy uncovered the regulatory effects of IMD-Pharma’s drug candidates on the immune system. He is entrepreneur and researcher of the university under the French act on innovation (12th of July 1999). Rémy advises IMD-Pharma on all bio-related subjects.
Biology R&D manager
Emily Clement (Ph.D.)
Emily has a strong expertise in oncology and immunology. She had worked on several academic projects in collaboration with IMD-Pharma before joining the team in January 2022. She is currently in charge of the non-clinical biology R&D.
Chemistry R&D manager
Abdel Oukhrib (Ph.D.)
Abdel has a strong expertise in dendrimer and terpene chemistry. He had worked on several academic projects in collaboration with IMD-Pharma before joining the team in January 2022. He is currently in charge of the non-clinical chemistry R&D.
Cofounder and advisor
Serge Calet (Ph.D.)
Serge has a strong knowledge in regulatory preclinical development and recognized expertise in managing and structuring small biotech companies (SC2S, Galchimia, Holis, Borochem…). During his career at SANOFI, he accompanied the preclinical development of more than 120 drug candidates. Serge advises IMD-Pharma on CMC.
Let’s get in touch
+33 (0)6 48 16 85 39
205 route de Narbonne (LCC-CNRS)
31077 Cedex 4